RxDoctor Payments Data

Kameko Oshiro, PA

Physician Assistant · Laguna Hills, CANPI 1225780059

Payments from drug & device makers

$9,585in general payments, 2019–2025

Across 383 payments — averaging $25.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AbbVie$1K
  • Boehringer Ingelheim$1K
  • Cequr Corporation$664
  • Bayer$619
  • Amgen$479
  • plus $4K from 46 others

What the payments were for

  • Travel & lodging$90%
  • Food & beverage$9,577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,585 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$121,310
Medicare patients
380
Services billed
2,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide41$39,622
OzempicSemaglutide36$37,518
TrulicityDulaglutide33$33,515
KerendiaFinerenone28$21,798
JardianceEmpagliflozin21$18,962
TradjentaLinagliptin14$10,213
NexletolBempedoic Acid14$7,954
Tresiba Flextouch U-100Insulin Degludec11$7,307
HumalogInsulin Lispro12$3,591
SynthroidLevothyroxine Sodium21$2,022
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,548
PaxlovidNirmatrelvir/Ritonavir19$1,429
Nano 2nd Gen Pen NeedlePen Needle, Diabetic15$1,137
Levothyroxine Sodium54$807
Atorvastatin Calcium45$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$1,584$76,72886 claims
Novo NordiskOzempic$445$37,51836 claims
Boehringer IngelheimJardiance, Tradjenta$1,018$29,17535 claims
BayerKerendia$619$21,79828 claims
Esperion Therapeutics, Inc.Nexletol$139$7,95414 claims
AbbVieSynthroid$1,298$2,02221 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →